

Celemics **CancerScreen** CDx Kit

Key Features

- Complete Coverage**

Cover all major concerning mutation for FDA approved therapies. Cover all coding exons in each gene.

- FASTQ to Clinical-grade Bioinformatics**

Experience our full bioinformatic support and customizable services. Includes pathogenicity, drug-association information, and functional information of target genes.

- Superior Performance in the Market**

Strong capture performance against GC rich regions with high coverage and uniformity. FFPE and low-quality specimen applicable.

- Rapid and Easy-to-use Workflow**

Expedite sequencing with no compromise on data quality with rapid one-day protocol. Simplify your workflow with no need for heavy instruments. Compatible to all automation liquid handlers.


Specifications

Product Name	CancerScreen CDx DNA Kit	CancerScreen CDx RNA Kit	CancerScreen CDx HRD Kit
Number of Genes	19	10	15
Target Size	48.7kb	33.0kb	71.5kb
Mutation Type	SNV, Indel, CNV, Rearrangement		
Covered Region	Whole CDS, Rearrangement		
Sample Type	FFPE, Fresh tissue, etc.		
Platform	All sequencers from Illumina and Thermo Fisher		
Bioinformatics Support	<ol style="list-style-type: none"> 1. Primary Analysis: FASTQ to annotated VCF 2. Secondary Analysis: CNV, Large InDel, Gene Rearrangement 3. Tertiary Analysis: Clinical interpretation 4. Visualization curation: Heatmap, CNV visualization, statistical analysis, etc. 		

Gene List of CancerScreen CDx Kits

	BRCA1	BRCA2	BRAF	EGFR	ERBB2	EZH2
DNA Panel	FGFR3	FLT3	IDH1	IDH2	KIT	KRAS
	MET	NF1	NRAS	PDGFRA	PDGFRB	PIK3CA
	TP53					
RNA Panel	ALK	ROS1	RET	NTRK1	NTRK2	NTRK3
	FGFR2	FGFR3	BCR	ABL1		
HRD Panel	ARID1A	ATM	ATRX	BAP1	BLM	BRIP1
	CHEK2	FANCC	MRE11	NBN	PALB2	RAD50
	WRN	BRCA1	BRCA2			

Bioinformatics and Clinical Report Example



List of variants for therapeutic use

Gene	Variant	Target therapy			
ALK	ALK Re.	Alectinib	Brigatinib	Ceritinib	Lorlatinib
ALK ROS1	ALK Re. or ROS1 Re.	Crizotinib			
BRAF	BRAF V600E or V600K Mut.	Binimetinib	Cobimetinib	Encorafenib	Trametinib
		Dabrafenib	Vemurafenib		
BRCA1 BRCA2	BRCA Mut.	Niraparib	Olaparib	Rucaparib	
BRCA1 BRCA2 ERBB2	BRCA Mut. and HER2 ⁻	Talazoparib			
EGFR	EGFR exon 19 Del. or exon 21 Mut.	Afatinib	Dacomitinib	Erlotinib	Gefitinib
		Osimertinib			
	EGFR exon 20 Ins.	Amivantamab	Mobocertinib		
EGFR RAS	EGFR ⁺ and RAS ^{WT}	Cetuximab	Panitumumab		
EGFR ERBB2	EGFR ⁺ and HER2 ⁺	Lapatinib			
ERBB2	HER2 ⁺	Trastuzumab	Marargetuximab	Neratinib	Pertuzumab
FGFR2	FGFR2 Re.	Infigratinib	Pemigatinib		
FGFR2 FGFR3	FGFR2 Re. or FGFR3 Mut.	Erdafitinib			
KIT	c-KIT Mut.	Imatinib	Regorafenib	Ripretinib	
KRAS	KRAS G12C Mut.	Sotorasib			
MET	MET exon 14 skipping	Cabozantinib	Capmatinib		
NTRK	NTRK fusion	Entrectinib	Larotrectinib		
PDGFRA	PDGFRA exon 18 Mut.	Avapritinib			
PIK3CA	PIK3CA Mut.	Alpelisib			
RET	RET fusion (or Mut.)	Pralsetinib	Selpercatinib		

Mut. : Mutation, Del. : Deletion, Ins. : Insertion, Re. : Rearrangement, WT : Wild-type, (+) : Positive, (-) : Negative